All In Biotech

Drug Trial Radar · NCT07355205

First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

A Phase Ib/II, Single-Center, Open-Label Study of First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer (FLINN)

Last checked: Nov 20, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

26

Planned (sponsor's estimate)

Start

Jul 7, 2026

Primary completion

Jul 31, 2032

Study completion Jul 31, 2032

Sponsor

Lead sponsor
Washington University School of MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
ImmunityBio, Inc.; The Foundation for Barnes-Jewish Hospital
First posted
Jan 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single center, phase Ib/II study combining an anti-PD-1 antibody and an anti-CTLA-4 antibody with IL-15. It is testing the hypothesis that the addition of nogapendekin alfa inbakicept to nivolumab and ipilimumab will augment the clinical activity of those two drugs.

Conditions

  • Non-small Cell Lung Cancer Stage IV
  • Non-small Cell Lung Cancer Recurrent

Interventions

  • IpilimumabDrug

    Ipilimumab will be given intravenously at a dose of 1mg/kg.

  • NivolumabDrug

    Nivolumab will be given intravenously at a dose of 360mg.

  • Nogapendekin alfa inbakiceptDrug

    Nogapendekin alfa inbakicept will be given subcutaneously at the assigned dose level.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS) (Phase Ib acceptable dose participants and Phase II participants)Time frame: Start of treatment through 2 years after end of treatment (up to 4 years)
  2. Incidence of dose-limiting toxicities (DLTs) (Phase Ib participants)Time frame: From start of treatment through completion of cycle 1 (each cycle is 42 days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.